Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

34 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2022.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28.8M shares of 122M outstanding shares and own 23.66% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), TPG GP A, LLC (4.32M shares), VR Adviser, LLC (3.05M shares), MAI Capital Management (2.04M shares), Rubric Capital Management LP (1.78M shares), Fairmount Funds Management LLC (1.62M shares), Altium Capital Management LP (1.28M shares), Frazier Life Sciences Management, L.P. (1.17M shares), ARMISTICE CAPITAL, LLC (416K shares), and EAM Investors, LLC (373K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.